RRC ID 38620
Author Kudo C, Yamakoshi H, Sato A, Nanjo H, Ohori H, Ishioka C, Iwabuchi Y, Shibata H.
Title Synthesis of 86 species of 1,5-diaryl-3-oxo-1,4-pentadienes analogs of curcumin can yield a good lead in vivo.
Journal BMC Pharmacol
Abstract BACKGROUND:Curcumin is known to possess many anti-tumor properties such as inhibition of tumor growth and induction of apotosis. However, limited bioavailability of curcumin prevents its clinical application. A synthesized curcumin analog, 1,5-diaryl-3-oxo-1,4-pentadiene such as GO-Y030, has the improved anti-tumor potential in vitro as well as in mouse model of colorectal carcinogenesis.
RESULTS:These compounds were divided into two groups; one is the higher anti-proliferative group, in which 79.7% of 1,5-diaryl-3-oxo-1,4-pentadienes were clustered. One of the 1,5-diaryl-3-oxo-1,4-pentadiene analogs, GO-Y078 has the most enhanced growth inhibition, and its solubility was improved, compared with curcumin. GO-Y078 inhibits NF-κB transactivation, as well as expression of TP53 and DR5 more effectively than curcumin. In a mouse model, GO-Y078 presented 1.4 fold more survival elongation that was not achieved by curcumin and GO-Y030.
CONCLUSIONS:The 1,5-diaryl-3-oxo-1,4-pentadiene analogs can yield good lead compounds for cancer chemotherapy, to overcome low bioavailability of curcumin.
Volume 11
Pages 4
Published 2011-5-28
DOI 10.1186/1471-2210-11-4
PII 1471-2210-11-4
PMID 21619659
PMC PMC3115866
MeSH Alkadienes / chemical synthesis* Alkadienes / pharmacology Alkadienes / therapeutic use Animals Antineoplastic Agents / chemical synthesis* Antineoplastic Agents / pharmacology Antineoplastic Agents / therapeutic use Apoptosis / drug effects Cell Line, Tumor Curcumin / analogs & derivatives* Curcumin / chemical synthesis Curcumin / pharmacology Curcumin / therapeutic use Drug Evaluation, Preclinical Humans Mice Mice, Inbred C57BL Solubility
IF 1.771
Resource
Human and Animal Cells HuCCT1(RCB1960) SH-10-TC(RCB1940) A431